NCT02236702

Kappa Opioid Receptor Imaging in Depression (KOR Depression)

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 15 (actual)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to use positron emission tomography (PET) imaging to measure the activity of the kappa opioid receptor (KOR) in the brains of depressed and non-depressed individuals.

Detailed description

The kappa opioid receptor (KOR) has been implicated in the etiology of fear, threat, and anhedonia in animal models of human depression psychopathology. Herein, we propose to study the KOR in vivo using positron emission tomography, and we will also measure the activity of the hypothalamic-pituitary-adrenal (HPA)-axis in all study participants. We propose to recruit up to N=50 medication-free individuals using a transdiagnostic approach, measure their KOR-selective radioligand \[11C\]LY2795050 volumes of distribution (VT), an equivalent of KOR availability using positron emission tomography (PET) and study the role of the KOR in mediating the quality and severity of the depressive phenotype.

Conditions

• Major Depressive Disorder
• Anhedonia

Interventions

Type	Name	Description
OTHER	Positron Emission Tomography (PET) imaging	Positron Emission Tomography (PET) imaging

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-03-01
• Completion: 2016-02-01
• First posted: 2014-09-10
• Last updated: 2016-08-17

Locations

1 site across 1 country: United States